Approving new drugs
| Autor: | John L. LaMattina |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Clinical Trials as Topic
Multidisciplinary United States Food and Drug Administration media_common.quotation_subject Public administration United States Food and drug administration Political science Humans Bureaucracy Safety Speculation Drug Approval Administration (government) Theme (narrative) media_common |
| Zdroj: | Science. 355:777-777 |
| ISSN: | 1095-9203 0036-8075 |
| DOI: | 10.1126/science.aam9914 |
| Popis: | As the Trump administration takes shape, there is much speculation as to what major changes will be made. A dominant theme of the Trump campaign was to cut through bureaucracy in Washington, D.C., thereby enhancing innovation and bringing new technology to Americans more quickly. Nowhere could such a philosophical change have more impact than on Food and Drug Administration (FDA) approval of new drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |